RecruitingPhase 1NCT04222413
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Studying Malignant peripheral nerve sheath tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Udo Rudloff, M.D., MDNational Cancer Institute (NCI)
- Intervention
- Metarrestin(drug)
- Enrollment
- 116 enrolled
- Eligibility
- 12-120 years · All sexes
- Timeline
- 2020 – 2028
Study locations (2)
- University of Kansas, Fairway, Kansas, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04222413 on ClinicalTrials.govOther trials for Malignant peripheral nerve sheath tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06693284A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]University of Minnesota
- RECRUITINGPHASE2NCT04872543A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)Memorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03872427Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyNational Cancer Institute (NCI)
- RECRUITINGNANCT03141021Multi-Institutional Registry for Malignant Peripheral Nerve Sheath TumorsWashington University School of Medicine
See all trials for Malignant peripheral nerve sheath tumor →